Effect of Empagliflozin On Liver Enzymes of Patients In Non-Alcoholic Steatohepatitis In Type 2 Diabetes Mellitus
| Autor: | Nauman Wazir, Shafqat Ur Rehman, Muhammad Arshad, Muhammad Zubair Wazir, Shehriyar Khan, Muhammad Saqib Ullah |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Journal of Gandhara Medical and Dental Sciences, Vol 10, Iss 2 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2312-9433 2618-1452 |
| DOI: | 10.37762/jgmds.10-2.375 |
| Popis: | OBJECTIVES To assess the effect of 10 mg and 25 mg once daily Empagliflozin on liver enzymes of patients of non-alcoholic steatohepatitis in patients of type 2 diabetes mellitus (T2DM). METHODOLOGY The study design was Quasi Experimental. Thirty three adult patients of Type 2 diabetes mellitus (T2DM) who were already on 2000 mg of Metformin and 100 mg of Sitagliptin and were having suboptimal glycemic control (HBA1C > 7% 0.05) decrease mean ALT levels in Group A pre-treatment and 12 weeks post-treatment. Similarly, there was a statistically significant (p > 0.05) decrease mean ALT levels in Group B pre-treatment and 12 weeks post-treatment. CONCLUSION Empagliflozin in both 10mg and 25 mg once daily doses cause statistically significant reduction in ALT levels in patients with NASH associated with T2DM |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|